Kura Oncology Advances Innovative Immunotherapy for Blood Cancer Treatment with GTB-3650

Innovative Immunotherapy Development in Blood Cancer Treatment

GT Biopharma, Inc. is making significant progress in the realm of cancer treatment with its immunotherapy drug, GTB-3650. The company recently completes a safety review for the third dosing group (Cohort 3) in its Phase 1 clinical trial, which involves patients suffering from relapsed or refractory blood cancers, predominantly acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The safety review reveals no issues with tolerability, allowing GT Biopharma to advance to Cohort 4, where patients will receive a higher dose of 10μg/kg/day. With patient screening underway, dosing is expected to commence shortly, signaling a promising step forward for patients who have not responded to existing treatments.

The Phase 1 study emphasizes the importance of enhancing the body’s immune response to combat cancer. GTB-3650 works by boosting the activity of natural killer cells, which play a vital role in identifying and destroying malignant cells. The treatment protocol involves continuous infusions for two weeks, followed by a two-week rest, and this cycle may be repeated for up to four months, depending on individual patient responses. So far, six patients have participated in the initial dosing cohorts, all exhibiting tolerability to the increasing dosages. Encouragingly, the trial shows promising trends in immunological biomarkers, which may indicate that the Cohort 4 dosing could represent a potential threshold for clinical efficacy.

The advancements made by GT Biopharma come at a time when the FDA acknowledges the need for innovative blood cancer treatments, recently approving the first once-daily menin inhibitor for relapsed NPM1-mutated AML. This reflects a broader industry trend towards targeted therapies that address specific cancer subtypes. GT Biopharma's commitment to tackling some of the most formidable cancer types through its advanced immunotherapy solutions is underscored by its upcoming comprehensive update, expected in the first quarter of 2026. As the company continues to explore the potential of GTB-3650, it remains poised to contribute significantly to the evolving landscape of cancer treatment.

In a related development, the focus on immunotherapy for blood cancers is increasingly gaining traction within the medical community. The growing recognition of targeted therapies is reshaping the future of oncology, making it a critical area for research and investment. For GT Biopharma, the successful progress of its clinical trials could pave the way for innovative treatment options that address unmet needs in cancer care, particularly for patients with limited alternatives.